ResearcherSun Yat-sen University Cancer CenterActive in the last 2 years

Dongsheng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9097-0956; OpenAlex author ID A5100342578. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, p… Last author DOI 10.1186/s12943-025-02437-0 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yun‐Xin Lu · 1 shared paper, 2025 · strength 0.20
- Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0 ↗
Feng Wang · 1 shared paper, 2025 · strength 0.20
- Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0 ↗
Feng‐Hua Wang · 1 shared paper, 2025 · strength 0.20
- Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0 ↗
Ming-Ming He · 1 shared paper, 2025 · strength 0.20
- Paper Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, si… DOI 10.1186/s12943-025-02437-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.